22.49
0.56 (2.55%)
| Penutupan Terdahulu | 21.93 |
| Jumlah Dagangan | 2,076,353 |
| Harga / Pendapatan (P/E Ke hadapan) | 119.05 |
| Harga / Jualan (P/S) | 382.23 |
| Harga / Buku (P/B) | 4.26 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,314.47% |
| EPS Cair (TTM) | -1.84 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 112.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 19.98 |
| Aliran Tunai Operasi (OCF TTM) | -140.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -99.00 M |
| Pulangan Atas Aset (ROA TTM) | -18.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | NewAmsterdam Pharma Company N.V | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.67 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 0.39% |
| % Dimiliki oleh Institusi | 111.32% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |